Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel in relapsed small cell lung cancer
NCT03219762Phase 2Unknown
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Feb 2017
- Primary completion
- Jan 2019
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nab-paclitaxel in small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC), neuroendocrine tumor of the lung, sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Status: unknown.
02
Drugs
nab-paclitaxel
03
Conditions
small cell lung cancer (SCLC)large cell neuroendocrine carcinoma (LCNEC)neuroendocrine tumor of the lung
Beyond the preview
Go deeper on NCT03219762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03219762.